Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021
August 05 2021 - 9:30AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage
biopharmaceutical company seeking to discover and develop
innovative medicines in areas of significant unmet medical need in
oncology and infectious diseases with a current focus on breast
cancer and COVID-19, today announces that Steven Quay, M.D., Ph.D.,
Atossa’s President and CEO, and Kyle Guse, Atossa’s Chief Financial
Officer, will participate at the BTIG Virtual Biotechnology
Conference on August 9-10, 2021.
Dr. Quay and Mr. Guse will participate in a fireside chat on
Monday, August 9, 2021, at 10:00 a.m. ET / 7:00 a.m. PT.
The live webcast will be available on the BTIG conference
website at the time of the event, after which it will be available
through BTIG research access.
Investors can also request a one-on-one meeting with Dr. Quay
and Mr. Guse to be arranged during the conference. Please contact a
BTIG conference representative.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical
company seeking to discover and develop innovative medicines in
areas of significant unmet medical need in oncology and infectious
diseases with a current focus on breast cancer and COVID-19. For
more information, please visit www.atossatherapeutics.com.
Forward-Looking Statements Disclaimer
Statement
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including,
without limitation, statements regarding the satisfaction of
closing conditions relating to the offering and the anticipated use
of proceeds from the offering, the risks and uncertainties
associated with any variation between interim and final clinical
results, actions and inactions by the FDA, the outcome or timing of
regulatory approvals needed by Atossa including those needed to
commence studies of AT-H201, AT-301 and Endoxifen, lower than
anticipated rate of patient enrollment, estimated market size of
drugs under development, the safety and efficacy of Atossa’s
products, performance of clinical research organizations and
investigators, obstacles resulting from proprietary rights held by
others such as patent rights, whether reduction in Ki-67 or any
other result from a neoadjuvant study is an approvable endpoint for
oral Endoxifen, and other risks detailed from time to time in
Atossa’s filings with the Securities and Exchange Commission,
including without limitation its periodic reports on Form 10-K and
10-Q, each as amended and supplemented from time to time.
Company Contact:Atossa Therapeutics, Inc.Kyle
Guse, CFO and General CounselOffice: 866
893-4927kyle.guse@atossainc.com
Investor Relations Contact:Core IROffice:(516)
222-2560ir@atossainc.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024